Study to evaluate intestinal glucose excretion using 18F-FDG-PET/MR enterography in patients taking imeglimi

Not Applicable

• Conditions: type 2 diabetes mellitus

• Registration Number: JPRN-UMIN000045345
• Lead Sponsor: Kobe university

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-10-01
• Study Completion: 2023-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

Not provided

Exclusion Criteria

1. patients with the following contraindications to Buscopan (butyl scopolamine bromide) patients with hemorrhagic colitis patients with angle-closure glaucoma patients with dysuria due to prostatic hypertrophy patients with severe heart disease patients with anesthetic ileus patients with a history of hypersensitivity to this drug 2. patients with dementia or psychiatric disorders 3. patients with possible intestinal perforation or obstruction 4. patients with metals in the body that cannot be tested by PET/MRE 5. pregnant or lactating patients 6. other patients who are judged unsuitable for this study by theinvestigator

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
FDG excretion into the intestine per hour

Secondary Outcome Measures

Name	Time	Method
Clinical parameters of blood biochemical test items such as HbA1c and blood glucose levels, and background factors of the research subjects (height, weight, gender, duration of diabetes, etc.)